Journal of Ginseng Research

The Korean Society of Ginseng (고려인삼학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Korean Red Ginseng Supplementation on Eradication Rate and Gastric Volatile Sulfur Compound Levels after Helicobacter pylori Eradication Therapy

  • Lee, So-Jung (Department of Gastroenterology, Gachon Graduate School of Medicine Gil Medical Center) ;
  • Park, Ji-Young (Department of Gastroenterology, Gachon Graduate School of Medicine Gil Medical Center) ;
  • Choi, Ki-Seok (Laboratory of Translational Medicine, Gachon University Lee Gil Ya Cancer and Diabetes Institute) ;
  • Ock, Chan-Young (Laboratory of Translational Medicine, Gachon University Lee Gil Ya Cancer and Diabetes Institute) ;
  • Hong, Kyung-Sook (Laboratory of Translational Medicine, Gachon University Lee Gil Ya Cancer and Diabetes Institute) ;
  • Kim, Yoon-Jae (Department of Gastroenterology, Gachon Graduate School of Medicine Gil Medical Center) ;
  • Chung, Jun-Won (Department of Gastroenterology, Gachon Graduate School of Medicine Gil Medical Center) ;
  • Hahm, Ki-Baik (Department of Gastroenterology, Gachon Graduate School of Medicine Gil Medical Center)
  • Received : 2010.02.16
  • Accepted : 2010.04.19
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

This clinical study was performed to evaluate whether supplementation of proton pump inhibitor (PPI)-based triple therapy with Korean red ginseng can enhance Helicobacter pylori (H. pylori) eradication and reduce levels of halitosis-associated volatile sulfur compounds (VSCs) in the stomach. Seventy-six patients were randomized into an eradication regimen-only group (n=45) or an eradication regimen plus 10 weeks of Korean red ginseng supplementation group (n=31). The eradication regimen consisted of PPI b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d.. for seven days. Korean red ginseng supplementation commenced on the last day of the eradication regimen. $^{13}C$-urea breath test and halimeter measurements were performed prior to protocol repetition. By intention-to-treat analysis, the H. pylori eradication rate in the Korean red ginseng group (77.4%, 24 of 31) was higher than that in the control group (45.0%, 26 of 45). However, by per protocol analysis, the eradication rate in the Korean red ginseng group was significantly higher than that in the control group (92.3%, 24/26 vs. 69.4%, 26/38; p<0.05). H. pylori infection was significantly associated with increased VSC levels. However, VSC levels decreased significantly in the Korean red ginseng group (p<0.05). In conclusion, supplementation of triple therapy with Korean red ginseng increased the H. pylori eradication rate and led to significant reductions in VSC levels, suggesting the usefulness of this substance in combating H. pylori infection.

Keywords

References

  1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186. https://doi.org/10.1056/NEJMra020542
  2. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789. https://doi.org/10.1056/NEJMoa001999
  3. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-1540. https://doi.org/10.1136/gut.2005.072009
  4. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194. https://doi.org/10.1001/jama.291.2.187
  5. Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, Miyoshi M, Yumoto E, Imagawa A, Toyokawa T, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 2007;25:805-812. https://doi.org/10.1111/j.1365-2036.2007.03268.x
  6. Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.
  7. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781. https://doi.org/10.1136/gut.2006.101634
  8. Lee JH, Cheon JH, Park MJ, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS. The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years. Korean J Gastroenterol 2005;46:94-98.
  9. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol ther 1999;13:1047-1055. https://doi.org/10.1046/j.1365-2036.1999.00555.x
  10. McLoughlin R, Racz I, Buckley M, O’Connor HJ, O’Morain C. Therapy of Helicobacter pylori. Helicobacter 2004;9:42-48.
  11. Gisbert JP, Pajares JM. Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-1057. https://doi.org/10.1046/j.1365-2036.2002.01276.x
  12. Gaby AR. Helicobacter pylori eradication: are there alternatives to antibiotics? Altern Med Rev 2001;6:355-366.
  13. Carson CF, Riley TV. Non-antibiotic therapies for infectious diseases. Commun Dis Intell 2003;27:S143-S146.
  14. Lee SY, Shin YW, Hahm KB. Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection. J Dig Dis 2008;9:129-139. https://doi.org/10.1111/j.1751-2980.2008.00334.x
  15. Zojaji H, Talaie R, Mirsattari D, Haghazali M, Molaei M, Mohsenian N, Derakhshan F, Zali MR. The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. Dig Liver Dis 2009;41:644-647. https://doi.org/10.1016/j.dld.2008.09.008
  16. Park S, Yeo M, Jin JH, Lee KM, Jung JY, Choue R, Cho SW, Hahm KB. Rescue of Helicobacter pylori-induced cytotoxicity by red ginseng. Dig Dis Sci 2005;50:1218-1227. https://doi.org/10.1007/s10620-005-2763-x
  17. Park S, Yeo M, Jin JH, Lee KM, Kim SS, Choi SY, Hahm KB. Inhibitory activities and attenuated expressions of 5-LOX with red ginseng in Helicobacter pylori-infected gastric epithelial cells. Dig Dis Sci 2007;52:973-982. https://doi.org/10.1007/s10620-006-9440-6
  18. Kim DK, Lee JA, Kim YB, Lee KM, Hahm KB. A randomized controlled trial assessing Korean red ginseng treatment of Helicobacter pylori-associated chronic gastritis.Korean J Med 2007;72:20-28.
  19. Lee JS, Kwon KA, Jung HS, Kim JH, Hahm KB. Korean red ginseng on Helicobacter pylori-induced halitosis: newer therapeutic strategy and a plausible mechanism. Digestion 2009;80:192-199. https://doi.org/10.1159/000229997
  20. Tangerman A. Halitosis in medicine: a review. Int Dent J 2002;52 Suppl 3:201-206. https://doi.org/10.1002/j.1875-595X.2002.tb00925.x
  21. Feller L, Blignaut E. Halitosis: a review. SADJ 2005;60:17-19.
  22. Porter SR, Scully C. Oral malodour (halitosis). BMJ 2006;333:632-635. https://doi.org/10.1136/bmj.38954.631968.AE
  23. Yoo SH, Jung HS, Sohn WS, Kim BH, Ku BH, Kim YS, Park SW, Hahm KB. Volatile sulfur compounds as a predictor for esophagogastroduodenal mucosal injury. Gut Liver 2008;2:113-118. https://doi.org/10.5009/gnl.2008.2.2.113
  24. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-1249. https://doi.org/10.1136/gut.2003.034629
  25. Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7-14. https://doi.org/10.1053/gast.2000.8550
  26. Kabir S. Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events. Helicobacter 2009;14:159-171. https://doi.org/10.1111/j.1523-5378.2009.00677.x
  27. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995;9:33-39.
  28. Kim JH, Kim HY, Kim NY, Kim SW, Kim JG, Kim JJ, Roe IH, Seo JK, Sim JG, Ahn H, et al. Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South Korea. J Gastroenterol Hepatol 2001;16:969-975. https://doi.org/10.1046/j.1440-1746.2001.02568.x
  29. Yim JY, Kim N, Choi SH, Kim YS, Cho KR, Kim SS, Seo GS, Kim HU, Baik GH, Sin CS, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340. https://doi.org/10.1111/j.1523-5378.2007.00504.x
  30. Kamiji MM, de Oliveira RB. Non-antibiotic therapies for Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2005;17:973-981. https://doi.org/10.1097/00042737-200509000-00014
  31. Zou J, Dong J, Yu XF. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy. Helicobacter 2009;14:119-127. https://doi.org/10.1111/j.1523-5378.2009.00666.x
  32. Cellini L, Di Campli E, Masulli M, Di Bartolomeo S, Allocati N. Inhibition of Helicobacter pylori by garlic extract (Allium sativum). FEMS Immunol Med Microbiol 1996;13:273-277. https://doi.org/10.1111/j.1574-695X.1996.tb00251.x
  33. Osato MS, Reddy SG, Graham DY. Osmotic effect of honey on growth and viability of Helicobacter pylori. Dig Dis Sci 1999;44:462-464. https://doi.org/10.1023/A:1026676517213
  34. Jones NL, Shabib S, Sherman PM. Capsaicin as an inhibitor of the growth of the gastric pathogen Helicobacter pylori. FEMS Microbiol Lett 1997;146:223-227. https://doi.org/10.1111/j.1574-6968.1997.tb10197.x
  35. Burger O, Ofek I, Tabak M, Weiss EI, Sharon N, Neeman I. A high molecular mass constituent of cranberry juice inhibits Helicobacter pylori adhesion to human gastric mucus. FEMS Immunol Med Microbiol 2000;29:295-301. https://doi.org/10.1111/j.1574-695X.2000.tb01537.x
  36. Nir Y, Potasman I, Stermer E, Tabak M, Neeman I. Controlled trial of the effect of cinnamon extract on Helicobacter pylori. Helicobacter 2000;5:94-97. https://doi.org/10.1046/j.1523-5378.2000.00014.x
  37. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008;13:261-268. https://doi.org/10.1111/j.1523-5378.2008.00601.x
  38. Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009;29:720-730. https://doi.org/10.1111/j.1365-2036.2009.03934.x
  39. Sezikli M, Cetinkaya ZA, Sezikli H, Guzelbulut F, Tiftikci A, Ince AT, Gokden Y, Yasar B, Atalay S, Kurdas OO. Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate? Helicobacter 2009;14:280-285. https://doi.org/10.1111/j.1523-5378.2009.00686.x
  40. Chuang CH, Sheu BS, Huang AH, Yang HB, Wu JJ. Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection. Helicobacter 2002;7:310-316. https://doi.org/10.1046/j.1523-5378.2002.00095.x
  41. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006;23:1077-1086. https://doi.org/10.1111/j.1365-2036.2006.02868.x
  42. Tiomny E, Arber N, Moshkowitz M, Peled Y, Gilat T. Halitosis and Helicobacter pylori. A possible link? J Clin Gastroenterol 1992;15:236-237. https://doi.org/10.1097/00004836-199210000-00013
  43. Ierardi E, Amoruso A, La Notte T, Francavilla R, Castellaneta S, Marrazza E, Monno RA, Francavilla A. Halitosis and Helicobacter pylori: a possible relationship. Dig Dis Sci 1998;43:2733-2737. https://doi.org/10.1023/A:1026619831442
  44. Hoshi K, Yamano Y, Mitsunaga A, Shimizu S, Kagawa J, Ogiuchi H. Gastrointestinal diseases and halitosis: association of gastric Helicobacter pylori infection. Int Dent J 2002;52:207-211. https://doi.org/10.1002/j.1875-595X.2002.tb00926.x
  45. Katsinelos P, Tziomalos K, Chatzimavroudis G, Vasiliadis T, Katsinelos T, Pilpilidis I, Triantafillidis I, Paroutoglou G, Papaziogas B. Eradication therapy in Helicobacter pylori-positive patients with halitosis: long-term outcome. Med Princ Pract 2007;16:119-123. https://doi.org/10.1159/000098364
  46. Lee H, Kho HS, Chung JW, Chung SC, Kim YK. Volatile sulfur compounds produced by Helicobacter pylori. J Clin Gastroenterol 2006;40:421-426. https://doi.org/10.1097/00004836-200605000-00011
  47. Choi KS, Lee SJ, Lee JS, Hong KS, Kim JG, Kim YJ, Hahm KB. Beneficial effect of Korean red ginseng on halitosis: attenuation of H2S induced inflammatory mediators and cystathionine $\gamma$-lyase expression. J Ginseng Res 2009;33:367-377. https://doi.org/10.5142/JGR.2009.33.4.367

Cited by

  1. : A Randomized Double Blind Placebo Controlled Study vol.2013, pp.1741-4288, 2013, https://doi.org/10.1155/2013/263805
  2. Chemoprevention of Gastrointestinal Cancer: The Reality and the Dream vol.7, pp.2, 2013, https://doi.org/10.5009/gnl.2013.7.2.137
  3. Ginseng for Health Care: A Systematic Review of Randomized Controlled Trials in Korean Literature vol.8, pp.4, 2013, https://doi.org/10.1371/journal.pone.0059978
  4. Korean Red Ginseng: Qualitative and Quantitative Benefits on Helicobacter pylori Infection vol.34, pp.2, 2010, https://doi.org/10.5142/jgr.2010.34.2.077
  5. Src and Syk are targeted to an anti-inflammatory ethanol extract of Aralia continentalis vol.143, pp.2, 2010, https://doi.org/10.1016/j.jep.2012.07.031
  6. Inhibition of Hydrogen Sulfide-induced Angiogenesis and Inflammation in Vascular Endothelial Cells: Potential Mechanisms of Gastric Cancer Prevention by Korean Red Ginseng vol.36, pp.2, 2012, https://doi.org/10.5142/jgr.2012.36.2.135
  7. Anti-Inflammatory Functions of Alverine via Targeting Src in the NF-κB Pathway vol.10, pp.4, 2010, https://doi.org/10.3390/biom10040611